Bristol-Myers Squibb Company

NYSE: BMY
$57.58
+$0.25 (+0.4%)
Closing Price on December 23, 2024

BMY Articles

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Mattel, NXP Semiconductor, Bristol-Myers, and Kraft Heinz all posted new 52-week lows Friday.
The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, National Oilwell Varco, Netflix and...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
Monday was a positive day for the broad U.S. markets with all three major indices posting a solid gain to start the week. Although the averages performed well in the session, Crude oil pulled back...
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Wednesday include Applied Materials, Celgene, Children's Place, Kinder Morgan, Match, Myriad Genetics, Nordstrom and Oracle.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Thursday include AMAG Pharmaceuticals, Baidu, Cisco, General Electric, Honeywell, 3M, Salesforce.com, SunPower and United...
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
24/7 Wall St. has put together a preview of Disney, General Motors, Twitter and other major companies scheduled to report their quarterly results this week.